IMARC Group, a leading market research company, has recently releases report titled “Mycoplasma Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” The study provides a detailed analysis of the industry, including the global mycoplasma testing market share, size, trends, and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights:
How big is the mycoplasma testing market?
The global mycoplasma testing market size reached US$ 813 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,679 Million by 2028, exhibiting a growth rate (CAGR) of 12.5% during 2023-2028.
What is Mycoplasma Testing?
Mycoplasma testing encompasses a diverse range of techniques and services aimed at detecting the presence of mycoplasma contamination in cell cultures and biopharmaceutical products. These testing services offer robust solutions to address the challenges associated with contamination, ensuring the integrity and efficacy of biological research and pharmaceutical production. Key features of mycoplasma testing services include sensitivity, specificity, and speed, enabling tailored solutions that meet the unique requirements of different industries, particularly pharmaceuticals and biotechnology.
Request for a sample copy of this report: https://www.imarcgroup.com/mycoplasma-testing-market/requestsample
What are the growth prospects and trends in the mycoplasma testing industry?
The increasing emphasis on the quality and safety of biopharmaceutical products represents one of the key factors driving the market growth. Regulatory agencies have set stringent guidelines for the absence of mycoplasma in final products, propelling the demand for effective testing methods. In addition to this, the growing biotechnology sector and the escalating investments in R&D activities have underscored the need for stringent quality control, including mycoplasma testing. The surge in demand for monoclonal antibodies, gene therapies, and other cell-based therapies has further highlighted the importance of ensuring contamination-free culture environments, thus catalyzing the market for mycoplasma testing services. Moreover, the rising awareness of the risks associated with mycoplasma contamination, such as altered cell function and unreliable research results, has led to increased demand for more advanced, rapid, and sensitive detection methods Biopharmaceutical companies aim to expedite the development and commercialization of their products, they seek high-throughput and reliable mycoplasma detection technologies, thereby driving market growth. The adoption of innovative technologies like PCR-based methods and next-generation sequencing in mycoplasma testing is gaining momentum, as these methods offer higher sensitivity and quicker results, is fueling the market growth. Furthermore, government initiatives supporting the advancement of the biopharmaceutical sector and the standardization of quality control measures are creating a positive outlook for the mycoplasma testing market across the globe.
What is included in market segmentation?
The report has segmented the market into the following categories:
Breakup by Product:
- Instruments
- Kits and Reagents
- Services
Breakup by Technology:
- NAAT (Nucleic Acid Amplification Technique)
- ELISA (Enzyme-linked Immunoassay)
- DNA Staining
- Others
Breakup by Application:
- Cell Line Testing
- Virus Testing
- End of Production Cells Testing
- Others
Breakup by End User:
- Academic Research Institutes
- Cell Banks
- Contract Research Organizations
- Pharmaceutical and Biotechnology Companies
- Others
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Who are the key players operating in the industry?
The report covers the major market players including:
- ATCC
- Bionique Testing Laboratories Inc. (Asahi Kasei Medical Co. Ltd.)
- Bio-Rad Laboratories Inc.
- Charles River Laboratories International Inc.
- Eurofins Scientific SE
- Invivogen
- Lonza Group
- Merck KGaA
- Roche Holding AG
- Sartorius AG
- Thermo Fisher Scientific Inc.
Browse the full report with TOC and List of Figures: https://www.imarcgroup.com/mycoplasma-testing-market
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email: sales@imarcgroup.com
LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/
